Click Here for 5% Off Your First Aladdin Purchase!
Call +1 (833) 552-7181 or Contact us Earn $25 in coupons on your first order with Aladdin!
Toggle Nav
My Cart
Search
Advanced Search
Menu
Sign In
྾
main product photo

Rapamycin (DMSO solution) - ≥98%, high purity , CAS No.53123-88-9, Inhibitor of FKBP prolyl isomerase 1A

  • Moligand™
  • ≥98%
Item Number
R276588
Grouped product items
SKUSizeAvailabilityPrice Qty
R276588-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$660.90
Add to Wish List Compare
Bulk Order  SDS  DATASHEET

Immunosuppressant

View related series
FKBP prolyl isomerase 1A Inhibitor

Basic Description

Synonyms(-)-Rapamycin|53123-88-9|AY 22989|AY-22989|I 2190A|I-2190A|I2190A|NSC 226080|RAPA|Rapammune|Rapamune|Rapamycin|SIIA 9268A|Sirolimus|Wy 090217|rapalimus|Supralimus|WY-090217|Rapamycin (Sirolimus)|HYFTOR|sirolimusum|Cypher|Antibiotic AY 22989|Rapamycin (GMP
Specifications & Purity≥98%
Storage TempProtected from light,Store at -20°C,Desiccated
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeINHIBITOR
Mechanism of actionInhibitor of FKBP prolyl isomerase 1A
Product Description

Store at -20°C. Store In the Dark. Store under desiccating conditions. This product is air and light sensitive and impurities can occur as a result of air oxidation or due to metabolism by microbes.

Associated Targets

FKBP1A Tclin Peptidyl-prolyl cis-trans isomerase FKBP1A 10 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

FKBP1B Tchem Peptidyl-prolyl cis-trans isomerase FKBP1B 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

FKBP5 Tchem Peptidyl-prolyl cis-trans isomerase FKBP5 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

EIF4E Tchem Eukaryotic translation initiation factor 4E 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

PDCD4 Tchem Programmed cell death protein 4 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

MTOR Tclin Serine/threonine-protein kinase mTOR 7 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Names and Identifiers

IUPAC Name (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
INCHI InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1
InChi Key QFJCIRLUMZQUOT-HPLJOQBZSA-N
Canonical SMILES CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)O)C)C)O)OC)C)C)C)OC
Isomeric SMILES C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC
RTECS VE6250000
PubChem CID 5284616
Molecular Weight 914.172
Reaxy-Rn 5848501

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Chemical and Physical Properties

SolubilitySupplied in DMSO (5mM)
Sensitivityair and light sensitive
Specific Rotation[α]-150° (C=0.2,MeOH)
Melt Point(°C)177 °C(dec.)

Safety and Hazards(GHS)

Pictogram(s) GHS08
Signal Danger
Hazard Statements

H351:Suspected of causing cancer

H372:Causes damage to organs through prolonged or repeated exposure

H361:Suspected of damaging fertility or the unborn child

Precautionary Statements

P280:Wear protective gloves/protective clothing/eye protection/face protection.

P405:Store locked up.

P501:Dispose of contents/container to ...

P264:Wash hands [and …] thoroughly after handling.

P260:Do not breathe dust/fume/gas/mist/vapors/spray.

P270:Do not eat, drink or smoke when using this product.

P203:Obtain, read and follow all safety instructions before use.

P318:if exposed or concerned, get medical advice.

P319:Get medical help if you feel unwell.

RTECS VE6250000
Reaxy-Rn 5848501
Merck Index 8114

Related Documents

 SDS

 Specification Sheet

References

1. Vasquez EM.  (2000)  Sirolimus: a new agent for prevention of renal allograft rejection..  Am J Health Syst Pharm,  57  (5): (437-48; quiz 449-51).  [PMID:10711524]
2. McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM et al..  (2011)  Efficacy and safety of sirolimus in lymphangioleiomyomatosis..  N Engl J Med,  364  (17): (1595-606).  [PMID:21410393]
3. Li J, Kim SG, Blenis J.  (2014)  Rapamycin: one drug, many effects..  Cell Metab,  19  (3): (373-9).  [PMID:24508508]
4. Kindrachuk J, Ork B, Hart BJ, Mazur S, Holbrook MR, Frieman MB, Traynor D, Johnson RF, Dyall J, Kuhn JH et al..  (2015)  Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis..  Antimicrob Agents Chemother,  59  (2): (1088-99).  [PMID:25487801]
5. Dyall J, Gross R, Kindrachuk J, Johnson RF, Olinger Jr GG, Hensley LE, Frieman MB, Jahrling PB.  (2017)  Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies..  Drugs,  77  (18): (1935-1966).  [PMID:29143192]
6. Kopparthy P, Murphy M.  (2021)  Rapid and Durable Response With Nab-Sirolimus After Everolimus Failure in a Patient With Perivascular Epithelioid Cell Tumors (PEComas) of the Uterus..  Cureus,  13  (5): (e14951).  [PMID:34123648]
7. Wagner AJ, Ravi V, Riedel RF, Ganjoo K, Van Tine BA, Chugh R, Cranmer L, Gordon EM, Hornick JL, Du H et al..  (2021)  nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors..  J Clin Oncol,  129  (3): (JCO2101728).  [PMID:34637337]
8. Chen J, Zheng XF, Brown EJ, Schreiber SL.  (1995)  Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue..  Proc Natl Acad Sci USA,  92  (11): (4947-51).  [PMID:7539137]
9. Chiu MI, Katz H, Berlin V.  (1994)  RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex..  Proc Natl Acad Sci USA,  91  (26): (12574-8).  [PMID:7809080]
10. Kelly PA, Gruber SA, Behbod F, Kahan BD.  (1997)  Sirolimus, a new, potent immunosuppressive agent..  Pharmacotherapy,  17  (6): (1148-56).  [PMID:9399599]
11. Vilella-Bach M, Nuzzi P, Fang Y, Chen J.  (1999)  The FKBP12-rapamycin-binding domain is required for FKBP12-rapamycin-associated protein kinase activity and G1 progression..  J Biol Chem,  274  (7): (4266-72).  [PMID:9933627]
12. Pollen AA et al..  (2019)  Establishing Cerebral Organoids as Models of Human-Specific Brain Evolution..  Cell,  176  (4): (743-756.e17).  [PMID:30735633]
13. Yazdankhah M et al..  (2020)  Modulating EGFR-MTORC1-autophagy as a potential therapy for persistent fetal vasculature (PFV) disease..  Autophagy,  16  (6): (1130-1142).  [PMID:31462148]

Solution Calculators

Privacy Policy Website Terms of Use Return policy Terms and Conditions of Sale Cookie Policy Sales Policy
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Copyright © 2023-present Aladdin Scientific Corp . All rights reserved.